

Selpercatinib LIBRETTO-001 (Cohort 4)

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Selpercatinib LIBRETTO-001 (Cohort 4)

FINAL SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Endocrine Tumours  
Therapeutic Indication: As monotherapy for the treatment of adult and adolescents  
≥12 years of age with advanced RET-mutant medullary thyroid cancer (MTC)  
Experimental Arm: Selpercatinib  
Control Arm: Single arm

